Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 11

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Cardiol. Nov 26, 2020; 12(11): 584-598
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.584

Full Size Figure Download Figure

Figure 6 Incidence of cardiomyopathy. CI: Confidence interval.

Citation: Nso N, Antwi-Amoabeng D, Beutler BD, Ulanja MB, Ghuman J, Hanfy A, Nimo-Boampong J, Atanga S, Doshi R, Enoru S, Gullapalli N. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World J Cardiol 2020; 12(11): 584-598
URL: https://www.wjgnet.com/1949-8462/full/v12/i11/584.htm
DOI: https://dx.doi.org/10.4330/wjc.v12.i11.584

Nso N, Antwi-Amoabeng D, Beutler BD, Ulanja MB, Ghuman J, Hanfy A, Nimo-Boampong J, Atanga S, Doshi R, Enoru S, Gullapalli N. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World J Cardiol 2020; 12(11): 584-598 [PMID: 33312443 DOI: 10.4330/wjc.v12.i11.584]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.